Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.

European journal of haematology - 1 Dec 2022

Díaz-Santa Johana, Rodríguez-Romanos Rocío, Coll Rosa, Osca Gemma, Pratcorona Marta, González-Bártulos Marta, Garrido Ana, Angona Anna, Talarn Carme, Tormo Mar, Arnan Montserrat, Vives Susanna, Salamero Olga, Tuset Esperanza, Lloveras Natàlia, Díez Isabel, Zamora Lurdes, Bargay Joan, Sampol Antonia, Cruz David, Vila Jordi, Sitges Marta, Garcia Antoni, Vall-Llovera Ferran, Esteve Jordi, Sierra Jorge, Gallardo David

Abstract excerpt

Acute myeloid leukemia (AML) is a complex disease, and its treatment needs to be adjusted to the risk, which is conferred by cytogenetics and molecular markers. Cytarabine is the main drug to treat AML, and it has been suggested that the genotype of cytarabine metabolizing enzymes may have a prognostic relevance in AML. Here we report the association between the 5'-nucleotidase, cytosolic II (NT5C2) rs10883841,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to 5'-Nucleotidase
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cytarabine
Share to Cytidine Deaminase
Share to Cytogenetic Analysis
Share to Leukemia, Myeloid, Acute
Share to Prognosis
Share to Remission Induction

Source

Identifiers

PMID: 36063368
DOI: 10.1111/ejh.13862

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.PMID 36063368Read ↗

NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia.Semantic proximity Read ↗

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.Semantic proximity Read ↗

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survivalSemantic proximity Read ↗

Pharmacogenomics and the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.Semantic proximity Read ↗

Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.Semantic proximity Read ↗

Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.Semantic proximity Read ↗

Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.Semantic proximity Read ↗

Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.Semantic proximity Read ↗

Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.Semantic proximity Read ↗

Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.